Gotham Asset Management LLC Boosts Stake in IQVIA Holdings Inc. (NYSE:IQV)

Gotham Asset Management LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,359 shares of the medical research company's stock after acquiring an additional 3,303 shares during the quarter. Gotham Asset Management LLC's holdings in IQVIA were worth $6,162,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new stake in IQVIA during the 4th quarter valued at about $33,000. GKV Capital Management Co. Inc. purchased a new stake in IQVIA during the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the 4th quarter valued at about $44,000. Zions Bancorporation N.A. boosted its holdings in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in IQVIA during the 4th quarter valued at about $60,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Up 1.6%

IQV stock traded up $2.23 on Friday, reaching $142.66. 2,227,287 shares of the company traded hands, compared to its average volume of 1,511,257. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a market cap of $24.68 billion, a P/E ratio of 19.02, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The firm has a fifty day simple moving average of $159.83 and a 200-day simple moving average of $186.07.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. During the same quarter last year, the company earned $2.54 EPS. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Morgan Stanley increased their price objective on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Hsbc Global Res cut IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Robert W. Baird dropped their price objective on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Barclays dropped their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. dropped their price objective on IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a report on Tuesday, February 18th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $230.76.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.